MedTrace Logo

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

NCT03500627 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-09-17

No results posted yet for this study

Summary

A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

OP-101

Intravenous Injection of OP-101 in healthy volunteers.

Sponsors & Collaborators

  • Orpheris, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen Huhn, MD · Orpheris, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2018-07-20
Completion
2018-07-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03500627 on ClinicalTrials.gov